rs192171304
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 10 ACMG points: 10P and 0B. PM2PP5_Very_Strong
The NM_000282.4(PCCA):c.1746G>A(p.Ser582Ser) variant causes a splice region, synonymous change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0000127 in 1,571,086 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Genomes: 𝑓 0.000013 ( 0 hom., cov: 31)
Exomes 𝑓: 0.000013 ( 0 hom. )
Consequence
PCCA
NM_000282.4 splice_region, synonymous
NM_000282.4 splice_region, synonymous
Scores
2
Splicing: ADA: 0.9379
1
1
Clinical Significance
Conservation
PhyloP100: -0.459
Genes affected
PCCA (HGNC:8653): (propionyl-CoA carboxylase subunit alpha) The protein encoded by this gene is the alpha subunit of the heterodimeric mitochondrial enzyme Propionyl-CoA carboxylase. PCCA encodes the biotin-binding region of this enzyme. Mutations in either PCCA or PCCB (encoding the beta subunit) lead to an enzyme deficiency resulting in propionic acidemia. Multiple transcript variants encoding different isoforms have been found for this gene.[provided by RefSeq, May 2010]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 10 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
PP5
Variant 13-100368574-G-A is Pathogenic according to our data. Variant chr13-100368574-G-A is described in ClinVar as [Likely_pathogenic]. Clinvar id is 556480.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
PCCA | NM_000282.4 | c.1746G>A | p.Ser582Ser | splice_region_variant, synonymous_variant | 19/24 | ENST00000376285.6 | NP_000273.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
PCCA | ENST00000376285.6 | c.1746G>A | p.Ser582Ser | splice_region_variant, synonymous_variant | 19/24 | 1 | NM_000282.4 | ENSP00000365462.1 |
Frequencies
GnomAD3 genomes AF: 0.0000132 AC: 2AN: 151292Hom.: 0 Cov.: 31
GnomAD3 genomes
AF:
AC:
2
AN:
151292
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.0000199 AC: 5AN: 251064Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135718
GnomAD3 exomes
AF:
AC:
5
AN:
251064
Hom.:
AF XY:
AC XY:
3
AN XY:
135718
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000127 AC: 18AN: 1419678Hom.: 0 Cov.: 25 AF XY: 0.0000197 AC XY: 14AN XY: 709150
GnomAD4 exome
AF:
AC:
18
AN:
1419678
Hom.:
Cov.:
25
AF XY:
AC XY:
14
AN XY:
709150
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0000132 AC: 2AN: 151408Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 73900
GnomAD4 genome
AF:
AC:
2
AN:
151408
Hom.:
Cov.:
31
AF XY:
AC XY:
0
AN XY:
73900
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:4Uncertain:1
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Propionic acidemia Pathogenic:3Uncertain:1
Uncertain significance, flagged submission | clinical testing | Counsyl | Jan 31, 2018 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Dec 14, 2023 | - - |
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Sep 05, 2023 | This variant has been observed in individual(s) with propionic acidemia (PMID: 15059621, 22033733). ClinVar contains an entry for this variant (Variation ID: 556480). Variants that disrupt the consensus splice site are a relatively common cause of aberrant splicing (PMID: 17576681, 9536098). Studies have shown that this variant results in skipping of exon 19 and introduces a premature termination codon (PMID: 15059621). The resulting mRNA is expected to undergo nonsense-mediated decay. This variant disrupts the c.1746G nucleotide in the PCCA gene. Other variant(s) that disrupt this nucleotide have been determined to be pathogenic (PMID: 31893529). This suggests that this nucleotide is clinically significant, and that variants that disrupt this position are likely to be disease-causing. For these reasons, this variant has been classified as Pathogenic. This variant is present in population databases (rs192171304, gnomAD 0.01%). This sequence change affects codon 582 of the PCCA mRNA. It is a 'silent' change, meaning that it does not change the encoded amino acid sequence of the PCCA protein. RNA analysis indicates that this variant induces altered splicing and may result in an absent or disrupted protein product. - |
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 21, 2019 | Variant summary: PCCA c.1746G>A (p.Ser582Ser) alters a non-conserved nucleotide located close to a canonical splice site and therefore could affect mRNA splicing, leading to a significantly altered protein sequence. Several computational tools predict a significant impact on normal splicing: One predict the variant abolishes a 5' splicing donor site. Four predict the variant weakens a 5' donor site. These predictions are supported by a functional study that reported an impact on mRNA splicing (Yang_2004). The variant allele was found at a frequency of 1.6e-05 in 245876 control chromosomes . c.1746G>A has been reported in the literature in a homozygote and compound heterozygote individuals affected with Propionic Acidemia (Yang_2004, Kraus_2012). The homozygote individual was found to have less than 10% PCC activity (Kraus_2012). These data indicate that the variant may be associated with disease. A ClinVar submission from a clinical diagnostic laboratory (evaluation after 2014) cites the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as pathogenic. - |
PCCA-related disorder Pathogenic:1
Likely pathogenic, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Feb 19, 2024 | The PCCA c.1746G>A variant is not predicted to result in an amino acid change (p.=). However, this variant is predicted to decrease the strength of a nearby canonical splice donor and may affect splicing (SpliceAI, Jaganathan et al. 2019. PubMed ID: 30661751). This variant was reported along with a frameshift variant in an individual with propionic acidemia, and RNA analysis indicated that this variant results in skipping of exon 19 (Yang et al. 2004. PubMed ID: 15059621). This variant is reported in 0.013% of alleles in individuals of South Asian descent in gnomAD. In ClinVar, this variant has conflicting interpretations including uncertain, likely pathogenic, and pathogenic. We interpret this variant to be likely pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
CADD
Benign
DANN
Benign
Splicing
Name
Calibrated prediction
Score
Prediction
dbscSNV1_ADA
Benign
dbscSNV1_RF
Pathogenic
SpliceAI score (max)
Details are displayed if max score is > 0.2
DS_DG_spliceai
Position offset: -13
DS_DL_spliceai
Position offset: 0
Find out detailed SpliceAI scores and Pangolin per-transcript scores at